Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Feldman Website

Steven A. Feldman, Ph.D.

Selected Publications

1)  Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, Restifo NP, Feldman SA, Rosenberg SA, Morgan RA.
A novel chimeric antigen receptor against PSCA mediates tumor destruction in a humanized mouse model of pancreatic cancer.
Hum. Gene Ther. 2014.
[Journal]
2)  Rosati SF, Parkhurst MR, Hong Y, Zheng Z, Feldman SA, Rao M, Abate-Daga D, Beard RE, Xu H, Black MA, Robbins PF, Schrump DA, Rosenberg SA, Morgan RA.
A Novel Murine T-Cell Receptor Targeting NY-ESO-1.
J. Immunother. 37: 135-146, 2014.
[Journal]
3)  Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, Feldman SA, Rosenberg SA, Morgan RA.
Development of a T Cell Receptor Targeting an HLA-A*0201 Restricted Epitope from the Cancer-Testis Antigen SSX2 for Adoptive Immunotherapy of Cancer.
PLoS ONE. 9: e93321, 2014.
[Journal]
4)  Casati A, Varghaei-Nahvi A, Feldman SA, Assenmacher M, Rosenberg SA, Dudley ME, Scheffold A.
Clinical-scale selection and viral transduction of human naïve and central memory CD8(+) T cells for adoptive cell therapy of cancer patients.
Cancer Immunol. Immunother. 2013.
[Journal]
5)  Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA.
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
Blood. 2013.
[Journal]
6)  Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy.
J. Immunother. 36: 133-51, 2013.
[Journal]
7)  Yang S, Karne NK, Goff SL, Black MA, Xu H, Bischof D, Cornetta K, Rosenberg SA, Morgan RA, Feldman SA.
A Simple and Effective Method to Generate Lentiviral Vectors for ex Vivo Gene Delivery to Mature Human Peripheral Blood Lymphocytes.
Hum Gene Ther Methods. 23: 73-83, 2012.
[Journal]
8)  Zhang L, Feldman SA, Zheng Z, Chinnasamy N, Xu H, Nahvi AV, Dudley ME, Rosenberg SA, Morgan RA.
Evaluation of γ-Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical Application.
J. Immunother. 35: 430-9, 2012.
[Journal]
9)  Morgan RA, Johnson LA, Davis J, Zheng Z, Woolard K, Feldman SA, Chinnasamy N, Kuan C, Song H, Zhang W, Fine HA, Rosenberg SA.
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
Hum Gene Ther. 23: 1043-53, 2012.
[Journal]
10)  Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME, Feldman SA, Rosenberg SA, Shurtleff SA, Rooney CM, Heslop HE, Dotti G.
Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?.
Mol. Ther. 20: 246-9, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/4/2014.